GLP-1 Heart Disease Independent Weight Loss: Key Benefits from 2026 Research Recent 2025-2026 research shows GLP-1 receptor agonists (GLP-1 RAs), including semaglutide/tirzepatide, provide significant GLP-1 heart disease risk reduction independent weight loss benefits. These drugs reduce risks of new-onset heart failure, major adverse cardiovascular events (MACE), cardiovascular death, and heart failure hospitalizations in patients with…
Read more
GLP-1 Heart Disease Risk Reduction Independent of Weight Loss: 2026 Research




















































